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Abstract
Background—Health insurance claims data may play an important role for healthcare systems 
and payers in monitoring the non-medical use of prescription opioids (NMPO) among patients. 
However, these systems require valid methods for identifying NMPO if they are to target 
individuals for intervention. Limited efforts have been made to define NMPO using administrative 
data available to health systems and payers. We conducted a systematic review of publications that 
defined and measured NMPO within health insurance claims databases in order to describe 
definitions of NMPO and identify areas for improvement.
Methods—We searched eight electronic databases for articles that included terms related to 
NMPO and health insurance claims. A total of 2,613 articles were identified in our search. Titles, 
abstracts, and article full texts were assessed according to predetermined inclusion/exclusion 
criteria. Following article selection, we extracted general information, conceptual and operational 
definitions of NMPO, methods used to validate operational definitions of NMPO, and rates of 
NMPO.
Results—A total of seven studies met all inclusion criteria. A range of conceptual NMPO 
definitions emerged, from concrete concepts of abuse to qualified definitions of probable misuse. 
Operational definitions also varied, ranging from variables that rely on diagnostic codes to those 
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that rely on opioid dosage and/or filling patterns. Quantitative validation of NMPO definitions was 
reported in three studies (e.g., receiver operating curves or logistic regression), with each study 
indicating adequate validity. Three studies reported qualitative validation, using face and content 
validity. One study reported no validation efforts. Rates of NMPO among the studies’ populations 
ranged from 0.75–10.32%.
Conclusions—Disparate definitions of NMPO emerged from the literature, with little 
uniformity in conceptualization and operationalization. Validation approaches were also limited, 
and rates of NMPO varied across studies. Future research should prospectively test and validate a 
construct of NMPO to disseminate to payers and health officials.
INTRODUCTION
Misuse, abuse, and dependence on opioid analgesic medications (referred to herein as the 
non-medical use of prescription opioids [NMPO]) and related consequences has become a 
critical public health issue in the US.1,2 From 1997 to 2007, there was a 402% increase in 
the average per person milligrams of prescription opioids sold in the US.3 In 2012, the 
number of persons who reported NMPO was 4.9 million, second only to marijuana use at 
18.9 million.4 Serious health ramifications have been associated with the NMPO 
epidemic.5–7 Those engaged in NMPO are likely to have mental and behavioral health 
comorbidities, such as post-traumatic stress, mood, anxiety, personality,8–12 and substance 
use disorders.9,10,13–16 Other common health problems include hepatitis10,13 and overall 
poorer health.9,17 The most severe health consequence resulting from the rapid escalation of 
NMPO has been the increase in opioid-related overdose deaths.18 From 1999–2008, 
overdose deaths increased fourfold,1 and in 2010, opioid overdoses claimed nearly 50 lives 
per day.18
Individuals engaged in NMPO are very likely to seek health care/services and subsequently 
represent a significant burden on the health care system. In the US, estimates of total societal 
costs of NMPO were $55.7 billion in 2007, with health care services (medical and 
prescription) accounting for 45% of those costs.19 To reduce the excess costs of NMPO and 
improve the health of populations served, health care systems and payers may benefit from 
using population-level administrative claims data to identify and intervene with those 
engaged in or at risk for NMPO. These systems require valid methods for identifying NMPO 
if they are to target patients or providers for intervention. However, definitions of NMPO 
vary across sources.20 Examples of benefits of a valid operational definition of NMPO could 
include payers having the capacity to identify patients at-risk or engaged in misuse then 
subsequently notifying providers. With such data, providers could provide prevention 
interventions (opioid contracts) or referrals and/or office-based treatment options 
(buprenorphine maintenance therapy).
The primary purpose of this article is to report findings from our systematic review of peer-
reviewed research publications that have defined and measured NMPO within 
administrative claims databases in order to describe: the existing variation in definitions, 
efforts to validate the various definitions of NMPO previously implemented in health 
insurance claims data, and the prevalence of NMPO.
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In spite of the far reaching impact of NMPO on individuals and the health care systems, 
current consensus does not exist for how to accurately identify NMPO within administrative 
claims data. Furthermore, NMPO has a variety of definitions within the literature, which 
leads to challenges for comparing prevalence rates and results across studies and reports. 
Table 1 contains examples of definitions or questions from leading national organizations in 
the US that are designed to describe or capture NMPO. The National Institute on Drug 
Abuse (NIDA) defines prescription medication abuse as: “…[T]he use of a medication 
without a prescription, in a way other than as prescribed, or for the experience or feelings 
elicited.”21 An additional commonly cited conceptualization of NMPO comes from the 
Substance Abuse and Mental Health Services Administration’s (SAMHSA) annual National 
Survey on Drug Use and Health (NSDUH). This survey asks participants regarding their: 
“…[U]se of any form of prescription pain relievers that were not prescribed for you or that 
you took only for the experience or feeling they caused.”22 The World Health Organization 
Composite International Diagnostic Interview23 asks patients if they “Have … ever used a 
pain killer nonmedically?” In addition to these conceptualizations of NMPO, one of the 
largest barriers to identifying patients with NMPO in administrative claims data is that while 
opioid use, abuse, and dependence are identifiable within the diagnostic codes of the 
International Classification of Diseases (ICD),24 NMPO is not a classified condition. Given 
the serious problems faced in the US regarding NMPO and the variation and limitations that 
exist regarding its definition, we initiated the current systematic review.
METHODS
Search Strategy
We began by searching eight electronic databases (CINAHL, Health Source: Nursing/
Academic Edition, Medline, PAIS International, PsychINFO, PsycArticles, PubMed, and 
Social Work Abstracts). These databases search a wealth of sources, including: peer-
reviewed literature, book chapters, conference proceedings, web content, dissertation 
publications, professional materials, legal sources, monographs, governmental documents, 
and technical reports. Within these databases, we searched for three broad categories of 
terms related to opioids (e.g., painkiller, analgesic), health insurance claims (e.g., benefits, 
claims, insurance), and non-medical use (e.g., misuse; dependence; Table 2). Given the fact 
that a variety of terms have been used to describe NMPO within the literature, a range of 
search terms were employed attempting to capture a majority of synonyms and subgroups. 
For example, based on the study of Manshikanti et al.,3 a list of opioid medications for 
which consumption has greatly increased, such as fentanyl and hydromorphone, were 
included as key terms under the opioids. Furthermore, we searched the National Library of 
Medicine Medical Subject Headings (MeSH) for relevant synonyms to our search terms 
related to opioids and administrative data. In addition to our broad conceptualization of 
opioid-related terms, we likewise chose broad terms to depict misuse (e.g., abuse, 
dependence, misuse) given the varied terminology used within the field. Our choice to 
maintain broad search terms stemmed from our interest in gathering all definitions of NMPO 
in health claims analyses rather than attempting to only identify a single a priori 
conceptualization. Search strings were organized by combining terms with Boolean 
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operators (i.e., AND and OR) in each of the eight databases. The three broad categories of 
terms were combined using the operator AND, while the subgroups of keywords within 
categories were listed using the operator OR (Table 2).
We reviewed publications from 2000 through February 2014. The year 2000 was selected as 
the first year for our search given escalating trends around that timeframe in the US for both 
elevated levels of NMPO25 and overdose death.26 Lastly, because the study aimed to 
investigate NMPO among enrollees of health insurance in the US, we limited our electronic 
search to studies conducted in the US.
Selection of Studies
Our initial search yielded a total of 2,613 studies (Figure 1), which were imported into an 
electronic database (Endnote X7.1) for review. We selected studies from this initial search in 
two steps. For the first step, two independent reviewers selected articles in which the titles 
and abstracts discussed prescription opioids or a conceptualization of NMPO, used 
administrative claims data, studied human patients, and utilized quantitative methodologies. 
Reviewers eliminated studies that were non-US based, duplicates, and conceptual/qualitative 
in nature (e.g., literature reviews and editorials; Figure 1). Conceptual/qualitative articles 
were not included given our specific intent to identify studies that developed definitions of 
NMPO for use within health claims data and subsequently reported results of the empirical 
implementation of those definitions. For articles found to be unclear in terms of the 
inclusion/exclusion criteria, the methods sections of these articles were examined. This step 
also involved discussions between reviewers to resolve disagreement and to protect the 
review from individual reviewer selection bias. A total of 2,569 studies were eliminated in 
this step, which resulted in 44 remaining studies (Figure 1). The second step of the study 
selection process was similar to the first, with the exception that the 44 remaining articles 
from the initial step were examined by the reviewers by reading both the abstract and full 
text and specifically only including studies that contained a conceptual and an operational 
definition of NMPO. Our final step also included examination of the reference lists within 
our selected studies to identify additional possible publications for inclusion, which yielded 
no additional studies that met our inclusion criteria.
Data Extraction and Analysis
The data extraction template for the final publications identified in the review was 
developed by the authors and was used by two reviewers during the extraction process to 
record general information; including first author, year of publication, and data source. 
Furthermore, the NMPO conceptualization used within the article title or abstract and 
operational definition of NMPO were also extracted. By NMPO conceptualization, we mean 
the brief nominal label or term the authors of the articles utilized to summarily describe their 
NMPO concept in the titles or abstracts (e.g., “prescription opioid abuse”). By operational 
definition, we mean the specific observed indicators utilized by the authors to operationalize 
and construct the NMPO variables from within their data sources (e.g., ICD-9 codes, dosage 
of medication). In addition, validation methods of the operationalized definition of NMPO 
(if one was included in the article), the general purpose of the analysis plan related to the 
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NMPO variable(s), a general description of the main outcomes, and the rates of NMPO 
reported were also added to the data extraction template.
RESULTS
We identified seven articles fitting our inclusion/exclusion criteria, including data from 
publicly funded insurance (n=2; Braker et al.,27 Leider et al.28), commercial health plans 
(n=3; Logan et al.,29 Rice et al.,13 White et al.10), and a mix of both publicly funded and 
commercial health plans (n=2; Roland et al.,30 Sullivan et al.31; Table 3).
Conceptualization of NMPO
The conceptual definitions of NMPO varied widely (Table 3). White et al.10, Rice et al.13, 
and Roland et al.30 all conceptually present NMPO as identifying prescription opioid 
abusers. Braker et al.27, Logan et al.,29 and Sullivan et al.31 discuss their conceptualizations 
of NMPO in terms of potential or probable misuse of opioid medications. Leider et al.28 
conceptualize their NMPO population as persons who chronically use opioids and are non-
adherent to their prescribed regimen.
Operationalization of NMPO
The operational definition of NMPO also varied widely across studies (Table 3). The 
operational definition of NMPO is constituted by the specific observed indicators utilized by 
the authors to construct the NMPO variables from within their data. Four general types of 
indicators were used by the authors to operationalize NMPO within the claims data: (a) 
ICD-9 diagnosis codes, (b) opioid medication prescription records, (c) provider/pharmacist 
records, and (d) urine toxicology information.
Roland et al.,30 White et al.10 et al., and Rice et al.13 each utilize diagnoses of opioid use 
disorders in their operational definitions of prescription drug abuse. In addition, White et 
al.10 et al. and Rice et al.13 also include in their definitions that patients must also possess 
evidence of an opioid medication prescription. Sullivan et al.31 and Braker et al.27 employ 
numbers of providers and pharmacists as part of their definitions of potential or probable 
NMPO. For instance, Braker et al.27 indicate patients must have had opioid medication 
prescriptions from two or more providers. However, added to the numbers of providers and 
pharmacists, Sullivan et al.31 also include information on days of opioids supplied (e.g., 91–
185, 186–240, >240 days), and Braker et al.27 include that patients must possess a record of 
having an opioid prescription. Similarly, Logan et al.29 utilize days of opioids supplied as 
well as doses of medications within their definition. Leider et al.28 likewise include days of 
opioids supplied combined with urine toxicology to verify non-adherence to the medication 
regimen (Table 3).
Validity
Two primary approaches, one quantitative and one qualitative, were employed in validating 
the operational definitions of NMPO in these studies (Table 4). Braker et al.27 employ a 
quantitative approach in which they performed a criterion validation using a receiver 
operating curve (ROC) analysis to identify how well their misuse score predicted whether or 
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not a patient had filled more than six opioid prescriptions in a six-month period. These 
authors reported adequate validity (sensitivity=0.82, specificity=0.70). Similarly, White et 
al.10 tested three statistical models (2 models with prescription claims information only as 
independent variables and 1 with integrated prescription and medical claims information as 
independent variables) to predict their NMPO variable. The prescription claims models 
contained similar opioid medication information (e.g., dosages) but differed in that one 
contained prescriber information and the other did not contain prescriber information. The 
integrated model included opioid medication information (similar to the 2 prescription 
information models) as well as health and mental health diagnoses previously demonstrated 
to be related to NMPO (e.g., depression, hepatitis).10 Employing an ROC analysis to 
identify model fit, these authors reported their integrated analytical model possessed the 
highest degree of validity in predicting their NMPO variable (C=0.93, r2=0.37). Sullivan et 
al.31 also performed a quantitative criterion validity analysis, and relied on logistic 
regression models that associated comorbid opioid use disorder diagnoses with their NMPO 
outcome variable (which was defined by pharmacy/provider data and days of opioid 
supplied). Results showed adequate support based on significant associations of the opioid 
use disorder diagnoses with their NMPO variable (commercial claims data [Health core]: 
Odds Ratio [OR] = 3.53, 95% Confidence Interval [CI] = 2.4–5.2; public claims data 
[Medicaid]: OR = 2.66, (95% CI= 1.1–6.2).
In contrast to these quantitative approaches, the second validation approach appears to be 
more conceptual (i.e., face and content validity; Table 4). These authors provided either 
rational justification of operational definitions and/or cited previous literature that showed 
support for the indicator they created. The only case wherein an operational definition with 
conceptual validation cited a previous study that had performed a quantitative validation was 
Rice et al.13 citing the previous work of White et al.10
Rates of NMPO
We also extracted rates of reported misuse from the articles by Logan et al.,29 Sullivan et 
al.,31 and Roland et al.30 The studies by Leider et al.,28 Rice et al.,13 and White et al.,10 did 
not specifically report rates of NMPO; however, the authors reported sufficient data to allow 
rates of NMPO to be calculated from their samples. The Braker et al.27 study neither 
reported rates of NMPO nor contained sufficient data to calculate rates of misuse (Table 4). 
Differences in rates range from the lowest at 0.75% (White et al.10 defining NMPO using a 
record of a opioid prescription combined with opioid use disorder diagnoses) to 10.32% 
(Logan et al.29 defining NMPO using prescription drug fill indicators). The calculation of 
the NMPO rate for Leider et al.28 was the total number of those likely non-adherent patients 
divided by total chronic users. The rate of NMPO for the Logan et al.29 study was the 
number of patients who had any one of four misuse/inappropriate prescribing factors divided 
by the total patients that received one or more prescription opioid medications from an 
emergency department. The rate of misuse from Sullivan et al.31 was calculated from the 
number of patients who were designated as having probable misuse divided by the total 
sample of chronic opioid users. For Rice et al. and Roland et al.,30 rates of misuse were 
based on the number of patients designated as abusers divided by the total patients within 
their samples. Rate of misuse for White et al.10 was also based on the number of patients 
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designated as abusers (n=875) divided by the total patients within their sample (n=116,382). 
This rate of misuse is from the drug claims model and not the integrated model due to the 
fact that the total number of abusers for the integrated model is not clearly reported.
DISCUSSION
This systematic review identified seven peer-reviewed research articles from 2000 to 2014 
that contain conceptual and operational definitions of NMPO that have been employed 
within public and private health insurance claims databases. Valid claims-based definitions 
of NMPO could help promote improved strategies for detecting and decreasing prescription 
opioid diversion and aid patients reduce NMPO and associated health problems. Our review 
found: (a) both the conceptual and operational definitions of NMPO are variable; (b) efforts 
have been made by authors of the studies to validate their definitions of NMPO, although 
these efforts are also variable, and (c) the variation among these studies likely has resulted in 
disparate rates of NMPO detected among the study samples drawn from the various claims 
databases.
Despite a focus in the reviewed articles on NMPO, the studies herein were unable to 
optimally validate NMPO using ‘gold standard’ measures. For example, while Sullivan et 
al.31 examined the association between their measure of NMPO and ICD-9 codes for opioid 
abuse and dependence, these codes include many instances of illicit opioid use (e.g. heroin) 
in addition to prescription abuse. Braker et al.27 examined the association of their NMPO 
variable with having six or more opioid prescriptions filled within six months, producing 
more of a validation of high use rather than misuse. Ideally, researchers could compare 
measures such as the Prescription Opioid Misuse Index32 or the Current Opioid Misuse 
Measure33 with the reviewed NMPO indicators to establish their validity. Although such a 
study is not easily accomplished, a prospective study that recruited patients within health 
plans for NMPO assessment would be feasible and could yield highly valuable data. Given 
the high level of heterogeneity of the definitions of NMPO within this review, the varying 
sources of data, the different analytical approaches used to quantify NMPO, and the lack of 
a gold-standard comparison, it is not possible to identify which particular definition NMPO 
should be recommended for general use.
The definitions of NMPO herein more likely approximate some degree of potential opioid 
medication misuse through patient behaviors and/or use disorder diagnoses. For instance 
Rice et al. and White et al.10 employed ICD diagnostic codes of opioid abuse, dependence, 
and overdose among individuals prescribed an opioid medication, which point to 
psychosocial factors likely at work within these patients that put them into a misuse 
category. However, a clear limitation is this definition does not account for those individuals 
with opioid use disorders who justifiably need and receive opioid pain management. 
Furthermore, the Logan et al.29 definition is likely indicative of problematic prescribing 
practices. However, given that the authors labeled their definition as including “misuse,” and 
the fact that they included behaviors such as overlapping opioid prescriptions; their 
conceptualization and operationalization of NMPO fell within our search parameters and 
aligned with similar behaviors noted within other studies included herein (e.g., Sullivan et 
al.31 included >186 days supply of opioid within 6 months).
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Other operational definitions rely on behavioral or medication utilization patterns that could 
be indicative of misuse. Accessing multiple opioid medications from multiple prescribers 
and pharmacies are important components of designating misuse.34,35 Furthermore, 
quantities of pills and dosages are also apparent indicators of misuse.36 However, among the 
authors that employed these parameters, only Sullivan et al.31 combine each of the ideas of 
multiple medications, prescribers, and pharmacies along with quantity. The combination of 
this nexus of indicators seems likely to reduce the number of false positive cases of NMPO. 
However, despite the value for using composite indicators, none of the studies using only 
health insurance administrative data can uncover whether individuals took the opioids for 
the purpose of getting “high” or the feelings produced thereby, as is central to definitions of 
NMPO utilized by SAMHSA or NIDA (Table 1). Furthermore, the addition of electronic 
health record information to a composite definition of NMPO may enhance the robustness 
and accuracy of a measure for identifying NMPO among patients.
Given the variety of definitions of NMPO among the studies examined within this review 
and the varying degrees of validation, rates of NMPO also appear to differ widely between 
studies. Rates of NMPO also are likely influenced by the populations studied. Specifically, 
the studies reviewed in this project were from public, private, and combined public and 
private sources, each sample adding a level of complexity for comparing NMPO rates. One 
possible solution to the variation in definitions we have presented herein would be for 
payers, health care systems, and researchers to unify constructs of NMPO under the auspices 
of organizing frameworks; such as that presented by the Analgesic, Anesthetic, and 
Addiction Clinical Trials, Translations, Innovations, Opportunities, and Networks 
(ACTTION) public-private partnership.37 Such an organizing framework could help 
delineate and systematize approaches to conceptualizing and operationalizing NMPO. 
However, the robustness of such approaches is somewhat restricted within the health claims 
environment based on limitations of data available for creating indicators— thus calling for 
possible changes in coding schemes and additional research to augment current practice.
Limitations
A primary limitation of this review is the high degree of variation within the individual 
studies identified, which has impacted our efforts to systematically categorize the definition 
of NMPO, validation approaches, and rates of NMPO. Indeed, we acknowledge our search 
terms were intentionally broad in order to capture all studies that examined a 
conceptualization of NMPO within claims data. As a result, we recognize we are not 
comparing studies with similar research aims, populations, and methods. However, given 
that the earliest studies for our current review were from 2009, this appears to indicate that 
the analysis of health insurance administrative data with the intention of identifying NMPO 
is new within the field, and therefore, the observed variation among definitions of the 
NMPO is expected. This limitation, nonetheless, underscores the fact that our review is 
timely in bringing together existing literature in the field.
A related limitation from our review is that a relatively small number of studies (N=7) were 
found for analysis. It may be the case that payers or investigators have examined this data, 
but have not published their findings, introducing publication bias in our review. However, 
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given the extensive and broad areas our selected databases search, we feel that non-peer-
reviewed materials or grey literature would likely have appeared in our final results had they 
met study inclusion criteria. Nevertheless, the number of studies we found presents 
challenges for categorizing clear patterns in the definitions of NMPO using claims data. 
However, as was noted, the relatively small number of studies likely is a product of the 
number of years that studies of NMPO in administrative claims data has been underway in 
the literature—calling for advancement in this field. We also recognize that identifying 
NMPO within health care claims data is inherently limited, not having the capacity to 
capture misuse patterns among individuals who obtain opioid medications without a 
prescription. Therefore, generalizability of findings from the studies reviewed herein and 
from our review is limited to populations within health care claims data.
Conclusion
The behaviors that constitute NMPO are unclear. In our review of studies, we found varying 
definitions of NMPO with limited consistency in conceptualization and operationalization. 
We found that validation of these definitions was also limited, and estimates of rates of 
opioid misuse were inconsistent. Future research should build on the current definitions of 
misuse presented herein and work to prospectively validate a construct of NMPO for 
dissemination to payers, clinicians, health care system administrators, and public health 
officials to accurately identify NMPO from claims data in order to better confront this 
national public health crisis.
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Table 1
Examples of definitions of opioid medication misuse
Organization Definitions and questions
American College of 
Preventive Medicine38
Non-medical use (prescription drug abuse, illicit use): Intentional or unintentional use of legitimately prescribed 
medication in an unprescribed manner for its psychic effect (either experimentation or recreationally), deciding 
to increase the dose of one’s own medication, unknowingly taking a larger dose than directed, engaging in a 
suicidal attempt or gesture, and inadvertent poisoning. The non-medical use of prescription medications implies 
that the person is using the drug for reasons other than those indicated in the prescribing literature or other off-
label uses prescribed by a clinician. Nonmedical use includes procurement of drugs for abuse, bartering, 
suicide, homicide, or accidental ingestion.
MedlinePlus39 If you take a medicine in a way that is different from what the doctor prescribed, it is called prescription drug 
abuse. It could be: 1) Taking a medicine that was prescribed for someone else; 2) Taking a larger dose than you 
are supposed to; 3) Taking the medicine in a different way than you are supposed to, this might be crushing 
tablets and then snorting or injecting them; 4) Using the medication for another purpose, such as getting high.
National Institute on Drug 
Abuse21
Prescription drug abuse is the use of a medication without a prescription, in a way other than as prescribed, or 
for the experience or feelings elicited.
Substance Abuse and 
Mental Health Services 
Administration’s annual 
National Survey on Drug 
Use and Health22
Use of any form of prescription pain relievers that were not prescribed for you or that you took only for the 
experience or feeling they caused.
World Health Organization: 
Composite International 
Diagnostic Interview23
Have you ever used a pain killer nonmedically?
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Table 2
Search strings/commanda
Opioid category AB (Analges* OR Buprenorphine OR Fentanyl OR Hydromorphone OR Morphine OR Opi* OR 
Oxycodone OR Oxymorphone OR Oxycontin OR Painkiller OR Pain Management OR Pain Medication 
OR Suboxone OR Subtex)
AND
Health insurance claims category (Admin* OR Benefi* OR Claim* OR Diversion* OR Enrollee OR Insur* OR Medicaid OR Medicare 
OR Pay*)
AND
Non-medically use category (Abuse OR Chronic OR Dependence OR Long-term OR Misuse OR Overuse)
a
Terms related to opioid medications were searched using the electronic database search engines within the title and abstract, and terms related to 
claims and misuse were searched using the electronic database search engines from any part of the article. This decision was based on very limited 
search results generated when all terms were only searched within titles and abstracts.
*
= Exploded mesh term encompassing all MeSH sub-headings.
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